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Expressed sequence tag profiling identifies developmental and anatomic partitioning of gene expression in the mouse prostate The prostate gland is an organ with highly specialized functional attributes that serves to enhance the fertility of mammalian species. Much  of the information pertaining to normal and pathological conditions affecting the prostate has been obtained through extensive develop- mental, biochemical and genetic analyses of rodent species. Although important insights can be obtained through detailed anatomical and  histological assessments of mouse and rat models, further mechanistic explanations are greatly aided through studies of gene and protein  expression. 
Abstract
Background: The prostate gland is an organ with highly specialized functional attributes that
serves to enhance the fertility of mammalian species. Much of the information pertaining to normal
and pathological conditions affecting the prostate has been obtained through extensive
developmental, biochemical and genetic analyses of rodent species. Although important insights can
be obtained through detailed anatomical and histological assessments of mouse and rat models,
further mechanistic explanations are greatly aided through studies of gene and protein expression.
Results: In this article we characterize the repertoire of genes expressed in the normal developing
mouse prostate through the analysis of 50,562 expressed sequence tags derived from 14 mouse
prostate cDNA libraries. Sequence assemblies and annotations identified 15,009 unique
transcriptional units of which more than 600 represent high quality assemblies without
corresponding annotations in public gene expression databases. Quantitative analyses demonstrate
distinct anatomical and developmental partitioning of prostate gene expression. This finding may
assist in the interpretation of comparative studies between human and mouse and guide the
development of new transgenic murine disease models. The identification of several novel genes is
reported, including a new member of the β-defensin gene family with prostate-restricted
expression.
Conclusions: These findings suggest a potential role for the prostate as a defensive barrier for
entry of pathogens into the genitourinary tract and, further, serve to emphasize the utility of the
continued evaluation of transcriptomes from a diverse repertoire of tissues and cell types.
Introduction
The normal function of the mammalian prostate gland is to
enhance fertility by secreting buffers, proteins and protective
agents that maintain sperm in a quiescent and intact state as
they pass through the male and female reproductive tracts [1].
Much of the information pertaining to normal prostate phys-
iology has been obtained through extensive developmental
and biochemical analyses of the prostates of rodent species.
Despite anatomical differences between rodents and humans,
these studies have been instrumental for elucidating the
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influence of androgens on prostate differentiation and
growth, and for characterizing the protein and mineral con-
stituents that comprise the unique prostate environment.
In humans, the prostate exhibits the distinctive attribute of
sustained growth throughout life, a situation that contributes
to both benign and malignant prostate pathologies [1]. Strik-
ingly, the prevalence rates of benign prostate hypertrophy
(BPH) and prostate carcinoma approach nearly 50% in Amer-
ican men by the age of 70 [2-4]. Despite extensive research
efforts, the etiologies of these diseases remain poorly defined.
In contrast to colon, skin and bladder epithelia, prostate epi-
thelial cells are thought to be relatively better protected from
environmental insults, and the cellular constituents exhibit
low proliferation rates [5]. Androgenic hormones and hered-
itary factors influence both BPH and prostate carcinoma, but
the specific mechanisms by which they alter cellular growth
remain to be delineated.
As with other human health disorders, rodent models have
been developed to aid in the scientific analysis of prostate dis-
eases. Whilst early efforts focused extensively on the rat pros-
tate [6,7] - in part due to the advantages of working with a
relatively large gland - recent investigations have utilized the
mouse increasingly, primarily as a result of the ease and
power of manipulating the mouse genome [8]. The rodent
prostate is comprised of four distinct lobes: ventral, anterior
(also termed the coagulating gland), dorsal and lateral; the
latter two are commonly grouped together and collectively
referred to as the dorsolateral lobe [9]. These lobes are
arranged circumferentially around the urethra and display
characteristic patterns of ductal branching and secretory pro-
tein production. In contrast, the human prostate lacks a
defined lobar architecture - it is organized in zones with dis-
tinct disease predispositions; carcinoma primarily develops
in the peripheral zone and benign hypertrophy primarily
occurs in the transition zone [10]. The anatomical and func-
tional relationships between the rodent prostate lobes and the
human prostate zones have not been definitively established,
though it has been suggested that the human peripheral zone
is most analogous to the rodent dorsolateral lobe based upon
the observation that tumors induced in rodent prostates gen-
erally arise in these locations [7,11].
Although important insights pertaining to normal develop-
ment and disease pathology can be obtained through detailed
anatomical and histological assessments of mouse models,
further mechanistic explanations are greatly aided through
studies of gene and protein expression. In this context, the
Cancer Genome Anatomy Project (CGAP) [12] and other
large-scale sequencing efforts have sought to provide a com-
prehensive sequence and reagent set that encompasses genes
expressed in diverse collections of human and mouse tissues
[13]. However, a recent inventory of cDNA libraries and
sequences archived in CGAP and the database of expressed
sequence tags (ESTs) indicates that while 838 cDNA libraries
have been constructed from murine tissues and cell types,
there is no mouse prostate representation (query 8.20.2003
in [12]). In this article we characterize the repertoire of genes
expressed in the normal developing mouse prostate through
the analysis of ESTs derived from mouse prostate cDNA
libraries. The results of this analysis demonstrate distinct
anatomical and developmental partitioning of gene expres-
sion, a finding that may assist in the interpretation of compar-
ative studies between human and mouse, and further guide
the evaluation and development of new transgenic murine
disease models. The identification of several novel genes is
reported, including a new member of the β-defensin gene
family with prostate-restricted expression. This finding sug-
gests a potential role for the prostate as a defensive barrier for
entry of pathogens into the genitourinary tract.
Results
Mouse prostate transcriptome
To assess the diversity of gene expression in the mouse pros-
tate, we constructed and characterized cDNA libraries repre-
senting distinct stages of prostate development and
maturation that began with the urogenital sinus (E16.5), and
continued with prostates from two day old (neonatal), ten day
old, 20 day old, 35 day old (puberty), three month old (normal
adult), and 14 month old (aged adult) animals (Figure 1). A
total of 62,046 ESTs were generated, of which 50,562 passed
stringent quality assessments. Of these, 4,299 ESTs anno-
tated to the mitochondrial genome. Assembly of the remain-
ing prostate ESTs into distinct clusters or transcription units
(TUs) was performed using the sequence assembly program
Phrap [14] and each TU was assigned an annotation by
BLAST comparisons against sequences in public databases.
In accordance with definitions used by the FANTOM and
RIKEN teams in assembling a mouse transcriptome using
full-length cDNAs [15], we use the term TU to designate a
cluster of transcripts or ESTs that contain a common core of
sequence information transcribed from a segment of the
genome. A TU may be defined by a single cDNA sequence or
by multiple overlapping ESTs that share a common core
sequence. Assembly and annotation of the 46,263 mouse
prostate ESTs produced 15,009 unique TUs. Of these, 4,550
TUs are composed of more than one EST and 10,459 TUs are
represented by a single EST. Of the 4,550 TUs that contain
more than one EST, 3,567 are represented by sequences
derived from more than one mouse prostate library. All
sequences are archived for public accession in the mouse
prostate expression database (mPEDB) [16,17].
Gene expression alterations during mouse prostate 
development
To identify genes potentially involved with prostate develop-
ment and maturation, we determined temporal expression
changes by calculating transcript abundance levels in cDNA
libraries constructed from different stages of prostate devel-
opment. Pairwise comparisons of the datasets from eachhttp://genomebiology.com/2003/4/12/R79 Genome Biology 2003,     Volume 4, Issue 12, Article R79       Abbott et al. R79.3
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timepoint were performed using Audic and Claverie's analy-
sis method [18]. At a significance level of p = 0.001, 285 genes
were differentially expressed between one or more time
points (see Additional data file 1, Table 1). Applying the Bonfer-
roni correction for multiple comparisons identified a cohort
of 69 genes with highly significant differential expression
between one or more developmental stages. Hierarchical
clustering of these genes demonstrated distinct temporal par-
titioning of gene expression with notable cohorts increasing
over time and others decreasing over time. In Figure 2, two
clusters of genes are highlighted which show progressive
increases or decreases in expression over time from urogeni-
tal sinus to adulthood. Several of these genes encode proteins
involved in specialized prostate secretory activity such as
spermine binding protein (Sbp) [19] and serine protease
inhibitor Kazal type 3 (Spink3) [20]. Several are also known
to be regulated by androgenic hormones, such as probasin
(Pbsn), and increase in expression following the onset of
puberty [21]. Other TUs with temporal changes in expression
have no currently identified functional roles in prostate
development.
Gene expression compartmentalization between 
mouse prostate lobes
The rodent prostate gland is comprised of four distinct ana-
tomical lobes: dorsal, lateral, ventral and anterior, each with
unique ductal branching patterns and different responses to
androgenic hormones (Figure 3) [22,23]. Studies of secretory
products from rodent prostates have identified specific
expression patterns that can be assigned to individual lobes
[24-26]. To further explore the functional differences
between mouse prostate lobes, we compared the profiles of
genes expressed in each lobe and identified 34 genes that
exhibited statistically significant differential expression. This
group was reduced to 17 genes after correcting for multiple
comparisons (Table 2). The expression patterns of these
genes clearly support conclusions of prior anatomical and
biochemical studies demonstrating functional heterogeneity
between lobes of the gland. Genes highly expressed in the
anterior prostate relative to the other lobes included onzin
(alias placenta specific 8; Plac8), pancreatic family type A
ribonuclease 1 (RNAse1), and experimental autoimmune
prostatitis antigen (Eapa1; a putative prostate transglutami-
nase), as well as several uncharacterized transcripts. Sper-
mine binding protein (Sbp), and serine protease Kazal type 3
(Spink3) are relatively highly expressed in the ventral lobe,
while transcripts with increased expression in the
Temporal events in mouse prostate development Figure 1
Temporal events in mouse prostate development. Androgen levels (solid line) rise beginning at day E12, fall shortly after birth, and rise again at puberty 
[65]. Branching morphogenesis (dashed line) begins at approximately day E17 with prostate budding, peaks at approximately day 10 (after birth), and is 
essentially complete before puberty by day 35 [23]. Peak DNA synthesis (dotted line), representing the development of the prostate epithelial and stromal 
cell mass, occurs at approximately day 35 [66]. cDNA libraries were constructed from prostate tissues obtained at defined points of prostate development 
(stars).
100%
90%
E12
E14
E16
E18
Birth
Day 5
Day 10
Day 15
Day 20
Day 25
Day 30
Day 35
Day 40
Day 45
80%
Peak DNA
synthesis
P
u
b
e
r
t
y
P
r
o
s
t
a
t
e
 
b
u
d
s
Peak branching
morphogenesis
Androgen level
Branching morphogenesis
DNA content
70%
60%
50%
40%
30%
20%
10%
0%R79.4 Genome Biology 2003,     Volume 4, Issue 12, Article R79       Abbott et al. http://genomebiology.com/2003/4/12/R79
Genome Biology 2003, 4:R79
dorsolateral prostate include receptor activity modifying pro-
tein 2 (Ramp2), a transcript with similarity to acrosomal ves-
icle protein-1, and several uncharacterized transcripts. We
determined the lobe-specific expression patterns of several
transcripts using quantitative PCR (QPCR), and found that
the EST and QPCR methods produced qualitatively similar
results (Figure 4).
Wubah et al. have reported the cloning and tissue distribution
of a transcript termed ventral prostate predominant 1 (Vpp1)
that was identified through mRNA differential display
between different mouse prostate lobes [27]. QPCR and vir-
tual expression analysis confirmed that the expression of
Vpp1 is primarily localized in the ventral prostate, with lower
but detectable levels of expression in the dorsolateral and
anterior prostate lobes (Figure 4).
Table 1
Characterized genes with enhanced prostate expression
SymbolUniGene description                                                               .TissuesUniGene ID
Svp2 Seminal vesicle protein 2 Genitourinary; aorta and vein Mm.1286
Msmb β-microseminoprotein Genitourinary Mm.2540
Galgt2UDP-N-acetyl-alpha-D-galactosamineColon; embryoMm.2807
Nkx3-1 NK-3 transcription factor locus 1 (Drosophila) Trophoblast stem cell Mm.3520
Svs6 Seminal vesicle secretion 6 Genitourinary Mm.3787
Sva Seminal vesicle antigen Genitourinary Mm.4119
Pbsn Probasin Genitourinary; bone Mm.8034
Defβ2 Defensin β 2 Head; epididymis Mm.41981
Sbp Spermine binding protein Tongue; genitourinary; stomach Mm.46428
B3galt1 B 1 3-galactosyltransferase polypeptide 1 Medulla oblongata; ganglion Mm.57041
Erbb3 Erythroblastic leukemia viral oncogene homolog 3 Tumor; inner ear Mm.57112
Hoxd12 Homeo box D12 Embryo; forelimb Mm.57124
- 11 kDa secreted protein precursor Whole skin Mm.71887
Mllt7 Mixed lineage-leukemia translocation to 7 homolog Tumor; genitourinary; spleen Mm.88827
Smok2 Sperm motility kinase 2 Lung Mm.88851
Svs7 Seminal vesicle protein secretion 7 Genitourinary Mm.99349
Fhl3 Four and a half LIM domains 3 Placenta Mm.100241
Pappa Pregnancy-associated plasma protein A Parthenogenote; tumor; genitourinary Mm.103481
Svs3 Seminal vesicle secretion 3 Genitourinary; adipose Mm.118769
- EST similar to Acrosomal vesicle protein 1 Genitourinary; thymus; placenta Mm.118804
Svs2 Seminal vesicle protein secretion 2 Genitourinary; aorta and vein Mm.143501
Amd2 S-adenosylmethionine decarboxylase 2 Blastocyst Mm.195848
Acac Acetyl-coenzyme A carboxylase Whole brain; branchial arches Mm.196688
Muc10 Mucin 10 submandibular gland salivary mucin Salivary gland Mm.200411
Lamc2 Laminin gamma2 chain Inner ear Mm.213197
Birc1f Baculoviral IAP repeat-containing 1f Lymph node; colon Mm.218759
Tnep1 Thrombospondin N-terminal domain Whole brain Mm.221237
Differential gene expression during mouse prostate development Figure 2 (see following page)
Differential gene expression during mouse prostate development. Statistical analysis of transcript abundance levels in stages of mouse prostate 
development identified 69 differentially expressed genes (p = 0.001). Shown are cohorts with progressing or regressing levels over time. The intensity 
scale represents the fold-change in expression normalized relative to the lowest abundance measurement.http://genomebiology.com/2003/4/12/R79 Genome Biology 2003,     Volume 4, Issue 12, Article R79       Abbott et al. R79.5
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Figure 2 (see legend on previous page)
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Our EST results demonstrated that the probasin transcript
was most highly expressed in the anterior prostate with lower
- but still high - transcript abundance levels in the dorsola-
teral lobes, and minimal expression in the ventral lobe (Fig-
ure 4). QPCR quantitated the highest probasin expression in
the dorsolateral lobes followed by the anterior prostate, with
lowest levels in the ventral lobe. These results differ from
studies of expression localization using the rat probasin pro-
moter to drive transgene expression in mouse prostate epi-
thelium where the highest levels were observed in the lateral
and dorsal lobes, with lower expression in the ventral prostate
and very low to absent expression in the anterior prostate
[11,28]. Subsequent immunohistochemical and Western
analyses with antibodies recognizing the mouse probasin pro-
tein demonstrated high levels of expression in the anterior as
well as the dorsolateral mouse prostate lobes [29]. These
results suggest that the rat probasin promoter may confer
slightly different cellular specificity compared with the native
mouse promoter, or that transgenic constructs alter the nor-
mal regional distribution of probasin expression.
Genes with expression enhanced or restricted to the 
mouse prostate
The comparative analysis of cDNA libraries representing the
repertoire of genes expressed in the mouse prostate provided
an opportunity to identify genes whose expression is
enhanced or restricted to the mouse prostate relative to other
normal tissues. The human prostate gland expresses several
transcripts and corresponding proteins in a highly tissue-
restricted manner including prostate specific antigen (PSA)
[30], human glandular kallikrein 2 (hK2) [31], prostase/
KLK4 [32] and prostate specific membrane antigen (PSMA)
[33]. Studies of these proteins have provided insights into
normal prostatic function, mechanisms of hormone-regu-
lated gene expression and the development of prostate
pathology. To identify transcripts preferentially expressed in
the mouse prostate, we assigned each prostate TU to a
UniGene cluster and then determined the tissue sources of all
ESTs comprising the cluster. In total, 776 prostate TUs were
mapped to UniGenes containing ESTs derived from three or
fewer other tissues (see Additional data file 2). Only 28 of
these TUs represent characterized genes (Table 1). Included
among the 28 are NKX3.1 and probasin, both of which are
known to have prostate-restricted patterns of expression
[29,34]. Most of the prostate-enhanced TUs are represented
by uncharacterized ESTs and full-length cDNAs sequenced by
the RIKEN mouse transcript sequencing project [15]. Eighty
TUs contained ESTs from at least two different prostate
libraries. Of these, eight represent spliced gene products
based on sequence comparisons with the mouse draft genome
sequence. An additional 20 TUs had interesting features,
such as high sequence conservation with human sequences,
and may represent orthologous genes.
Identification of a gene encoding a putative prostate-
specific β-defensin
One TU, originally designated TU23348 after the original
library clone identifier, was found to be expressed in multiple
mouse prostate cDNAs libraries, lack representation in the
UniGene or dbEST sequence databases, and exhibit sequence
similarities to genes in the β-defensin family. We reasoned
that since TUs specifically originating from the mouse pros-
tate were not represented in the public sequence databases,
TU23348 could represent a β-defensin with expression
restricted to the prostate. To evaluate this possibility, we
measured the relative abundance of TU23348 transcripts in
multiple mouse tissues by QPCR. These results confirmed
high levels of TU23348 expression in the prostate, with very
low levels in testis and skeletal muscle, and no detectable
transcripts in a wide range of other tissues (Figure 5a). A
multiple tissue mRNA blot confirmed the RT-PCR findings
(Figure 5b), and northern analysis identified a transcript size
of approximately 0.4 kb. Northern analysis and QPCR also
indicated that TU23348 expression is further compartmen-
talized within the mouse prostate having highest expression
levels in the dorsolateral and ventral lobes, with very low to
absent expression in the anterior prostate (Figure 5c).
A full-length TU23348 transcript was obtained through
assemblies of mouse prostate cDNAs and by 5' and 3' rapid
amplification of cDNA ends (RACE) reactions using mouse
prostate cDNA as a template. The coding sequence comprises
219 nucleotides encoding a predicted polypeptide of 73 amino
acids (Figure 6a). The nucleotide sequence comprises a 72 nt
A schematic diagram of the adult mouse genitourinary tract (lateral view),  with the anatomically-distinct prostate lobes highlighted in gray Figure 3
A schematic diagram of the adult mouse genitourinary tract (lateral view), 
with the anatomically-distinct prostate lobes highlighted in gray. 
Reproduced with permission from [67,68].
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5' UTR and 111 nt 3' UTR with putative polyadenylation
sequences located 99, 72 and 51 nt upstream of the polyA tail.
Protein sequence alignments with members of the mouse and
rat β-defensin family demonstrate a high level of sequence
similarity including conservation of the majority of the
cysteine and positively-charged residues that are predicted to
modulate antimicrobial activity (Figure 6) [35,36]. Align-
ments of the TU23348 transcript with the draft mouse
genome sequence indicates that TU23348 is located on
chromosome 8 and is comprised of two exons; the first encod-
ing 19 amino acids and the second 54 amino acids. The exons
are separated by a 7.3 kb intron (Figure 6). The gene is located
between two other members of the β-defensin family, β-
defensin 1 and 2. We named this gene Pbd1 for prostate β-
defensin 1. Subsequently, in accordance with the Human
Genome Organization (HUGO) nomenclature committee,
this gene carries the official designation of Defβ37  for
defensin beta 37 as it is the 37th β-defensin reported. The
sequence is represented in GenBank under accession number
AY387658.
Discussion
The physiological and biochemical features of a particular tis-
sue or cell type represent the complex endpoint of interac-
tions between specific cohorts of expressed genes and the
environment. The identification of the complete set of genes
expressed in the mouse has been the focal point of intensive
efforts involving the sequence analysis of hundreds of cDNA
libraries derived from tissues at different stages of mouse
development [15]. The ultimate success of this approach
depends on the specific organs, tissues and cell types selected
for sampling. Many transcripts will be expressed in a tissue-
or cell type-restricted manner, while others are expressed
Comparative analysis of fold change of gene expression in adult prostate lobes using quantitative PCR (QPCR) (dark grey bars) and virtual EST  measurements (light grey bars) Figure 4
Comparative analysis of fold change of gene expression in adult prostate lobes using quantitative PCR (QPCR) (dark grey bars) and virtual EST 
measurements (light gray bars).
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only in response to specific stimuli or at precise stages of
development [15,37]. Indeed, despite the comprehensive
analysis and assembly of more than two million mouse
cDNAs and ESTs into about 37,000 distinct TUs, a subse-
quent report focusing on genes expressed in murine macro-
phages and dendritic cells identified more than 300 high
quality TUs that had not been identified in the comprehensive
study [37].
Despite the prominence of diseases affecting the prostate
gland and the development of numerous mouse models to
evaluate prostate pathology, there are no reports of
comprehensive gene expression studies of the normal mouse
prostate. In addition, normal mouse prostate EST resources
are not included in public sequence data repositories. In part
this may reflect the difficulties encountered in working with
organs of very small size, as well as the presence of high levels
of endogenous RNAses in the mouse prostate gland. The anal-
ysis of the prostate transcriptome reported here is based on
the assembly of >50,000 ESTs derived from 14 cDNA librar-
ies constructed from distinct anatomical regions and develop-
mental stages. A total of 15,009 TUs were defined by 4,550
clusters and 10,459 singleton sequences. These TUs anno-
tated to 9,882 known genes leaving 5,127 as potentially novel
uncharacterized transcripts. Of the uncharacterized TUs, 683
exhibited an open reading frame of at least 100 amino acids.
The remaining 4,444 TUs may comprise 5' or 3' untranslated
regions of protein-coding genes, or possibly non-coding
RNAs. This number represents ~30% of all distinct prostate
TUs, a number in good agreement with conclusions reached
from analyses of the RIKEN mouse EST dataset in which
11,665 TUs or about 35% of all TUs were determined to be
non-coding transcripts [15]. While the functional significance
of these mRNAs has not been determined, non-coding RNAs
may be of importance in normal and pathological processes
affecting the prostate. Two human genes, PCGEM1 and DD3,
appear to produce non-coding transcripts that are
overexpressed in human prostate carcinoma relative to
benign tissue counterparts [38,39].
In the mouse, structures comprising the urogenital sinus
develop beginning at day 13 post conception with prostate
buds forming late on day 17, a developmental stage roughly
correlating with the maximum production of testosterone by
the fetal testis [1]. At birth, androgen receptor activity is
detected primarily in mesenchymal cell types comprising the
prostate stroma with a subsequent transition to expression in
the secretory epithelium following their differentiation from
basal epithelium. To identify genes potentially involved with
prostate development, we determined temporal expression
changes by measuring transcript abundance levels in cDNA
libraries constructed from distinct stages of maturation.
Genes involved in specialized prostate secretory function
demonstrated temporal expression increases coinciding with
Table 2
Genes with relative differential expression between mouse prostate lobes (p = 0.001 using the Bonferroni correction) with normalized 
EST numbers
SymbolDescriptionUniGene               Species IDESTs per lobe
VP AP DLP
Sbp Spermine binding protein Mm.46428 6313 36181 01 20761
Spink3 Serine protease inhibitor Kazal type 3 Mm.272 6296 12421 01 5941
Vpp1 Ventral prostate predominant 1 Mm.157655 5394 5831 2001,2 4202
Ramp2 Receptor (calcitonin) activity modifying protein 2 Mm.218611 4672 421 48 1571
Defβ37 Novel prostate β-defensin 37 - 10164 38 01 971
A430096B05Rik RIKEN cDNA A430096B05 Mm.205520 4722 331 1471 78
Pbsn Probasin Mm.8034 5239 231 11001 3111
Eapa1 Experimental autoimmune prostatitis antigen 1 Mm.221277 5446 181 3791 1681
Prdx6 Peroxiredoxin 6 Mm.6587 2712 151,2 1871 862
B2m β-2 microglobulin Mm.163 5263 31,2 1131 572
Svs2 Seminal vesicle protein secretion 2 Mm.143501 1342 21 1871,2 22
9530003J23Rik RIKEN cDNA 9530003J23 Mm.118350 5050 21 1701,2 02
RNAse1 Ribonuclease 1 pancreatic Mm.3412 4606 01 2481 691
Plac8 Onzin (placenta-specific 8) Mm.34609 5767 01 571 2
Svs5 Seminal vesicle secretion 5 Mm.140154 506 01 31 441
- ESTs similar to acrosomal vesicle protein 1 Mm.118804 2570 01 262 1431,2
1,2 Statistically significant gene expression comparisons between lobes are denoted by shared superscripts. VP, ventral prostate; AP, anterior 
prostate; DLP, dorsolateral prostate.http://genomebiology.com/2003/4/12/R79 Genome Biology 2003,     Volume 4, Issue 12, Article R79       Abbott et al. R79.9
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prostate maturation and the production of testosterone at
puberty. These genes include several that encode seminal
fluid proteins such as Svs2, Svs5 and Sbp. The expression of
probasin, a gene known to be regulated by androgens,
followed a similar pattern of expression. Transcripts encod-
ing the antioxidant protein peroxiredoxin 6 (Prdx6) (alias
antioxidant protein 2: Aop2) also increased with age. Prdx6 is
involved in the redox regulation of the cell and can reduce
Prostate-specific expression of a novel β-defensin gene (Defβ37/Pbd1) Figure 5
Prostate-specific expression of a novel β-defensin gene (Defβ37/Pbd1). (a) Dot blots comprised of mRNAs derived from multiple normal mouse tissues 
were hybridized with probes encoding the Defβ37/Pbd1 gene, exposed to a phosphorimage screen, and quantitated. Tissue signal intensities are reported 
in arbitrary units above background intensity. (b) Prostate-specific expression of a novel β-defensin gene (Defβ37/Pbd1). QPCR analysis of Defβ37/Pbd1 
expression in multiple normal mouse tissues and in dissected mouse prostate lobes. Expression levels reflect the relative fold-differences in transcript 
abundance between tissue samples. Very low levels of Defβ37/Pbd1 expression not visible on this plot were detectable in skeletal muscle and testis 
(asterisks). (c) Prostate-specific expression of a novel β-defensin gene (Defβ37/Pbd1). Northern analysis of Defβ37/Pbd1 expression in dissected individual 
mouse prostate lobes.
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Figure 6 (see legend on next page)
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H2O2, short chain fatty acids and phospholipid hydroperox-
ides [40]. The expression of such redox-modulating enzymes
may assist in modulating the unusual high zinc/high citrate
biochemical phenotype described in the human prostate
microenvironment [41]. α-tubulin, dynein and other genes
involved in motility and the cytoskeleton were maximally
expressed in neonatal prostate with diminished expression
correlating with gland maturation. Genes involved in energy
metabolism such as Cox6c and ATP5l were similarly highly
expressed early in prostate development. Surprisingly, tran-
scripts encoding α- and β-globin were measured at high levels
early in development, suggesting that silencing mechanisms
restricting globin expression to red blood cell lineages are yet
to be operative [42]. Other studies have identified globin gene
expression in non-erythroid cell types in response to specific
stimuli [43], and it has been hypothesized that globin pro-
teins may function not only to carry oxygen, but may also par-
ticipate in other cellular processes [43,44]. Interestingly, one
of the first mouse models of prostate carcinoma was
developed inadvertently using the human γ-globin promoter
to drive expression of the SV40T antigen [45,46]. The exper-
imental objective of the γ-globulin/SV40T transgenic mouse
was to produce a model of erythroleukemia, but tumors of the
prostate, adrenal cortex and brown adipose resulted from the
genetic manipulation, indicating that the human γ-globin
promoter exerts activity in prostate epithelial cells.
We further characterized one novel prostate TU, now desig-
nated Defβ37/Pbd1, which exhibits high sequence homology
with the β-defensin gene family. Alignment of the Defβ37/
Pbd1 sequence with the draft mouse genome sequence placed
it between two members of the β-defensin family, β-defensin
1 and 2, located on chromosome 8. No mouse ESTs annotated
to this region, suggesting that Defβ37/Pbd1 was restricted in
expression to the prostate. We confirmed the prostate-local-
ized expression of Defβ37/Pbd1 by QPCR and northern anal-
ysis. The products of the defensin gene family function as
cationic antimicrobial peptides and serve as components of
the phagocytic and epithelial innate host defense system [47].
A recent report indicates that the β-defensin family now com-
prises at least 43 members in the mouse, organized into five
clusters located on chromosomes 1, 2 (two clusters), 8 and 14,
with orthologs present on corresponding chromosomal
regions in the human genome [35]. While most of the
characterized β-defensins are expressed in many tissues, sev-
eral have been identified with expression restricted to organs
such as the epididymis and testis [48]. Other peptides with
antimicrobial features and sequence similarity to the
defensins have also been identified, such as the rat Bin1b pro-
tein that is expressed exclusively in the epididymis [49]. In
addition to antimicrobial activity, the defensins have also
been shown to influence non-specific cytotoxicity, membrane
permeability and chemotaxis. They also function as sperm-
immobilizing agents and have cytotoxicity toward oocytes
and preimplantion embryos [47,50]. As with other regions of
the genitourinary tract, the prostate gland is subject to infec-
tion by bacteria and other pathogens resulting in the clinical
diagnosis of prostatitis. Thus, Defβ37/Pbd1 may have a role in
preventing infectious disease within the prostate, or if secreted
into seminal fluid it may function to modulate fertility.
This study represents the first global analysis of transcript
expression in the mouse prostate, and provides both a virtual
as well as a physical resource for further studies of prostate
development, physiology and pathology. Comparative studies
of mouse and human prostate gene expression may assist in
determining the functional equivalents between the lobar and
zonal anatomies of the mouse and human prostates, respec-
tively. Exploiting the regulatory mechanisms dictating pros-
tate-specific and androgen-regulated gene expression may
also assist in the development of new transgenic models and
provide for a more complete understanding of hormonal reg-
ulation. The identification of previously uncharacterized
transcripts such as Defβ37/Pbd1  serves to emphasize the
need to evaluate transcriptomes from a diverse repertoire of
tissues and cell types in order to catalog completely the genes
expressed in mammalian species.
Methods
cDNA library construction and DNA sequence analysis
Male C57Bl6J mice (Jackson Labs, Maine, USA) of defined
ages were sacrificed in accordance with institutional proto-
cols. Whole urogenital sinus (UGS) or individual prostate
lobes were dissected, pooled and snap frozen in liquid nitro-
gen. Tissues were homogenized using a Polytron PT-MR-
2100 rotor stator homogenizer (Kinematica, Switzerland)
and total RNA was purified using Qiagen RNeasy purification
Sequence analysis of Defβ37/Pdb1 Figure 6 (see previous page)
Sequence analysis of Defβ37/Pdb1. (a) The full-length mouse Defβ37/Pbd1 sequence was obtained through the assembly of mouse prostate ESTs and RACE 
reactions. The open reading frame (capital small font) comprises 219 nt encoding a putative protein of 73 amino acids. Three potential polyadenylation 
signals are located 99, 72 and 51 nt upstream of the polyA sequence (dashed underline). The Defβ37/Pbd1 gene is predicted to have two exons (splice site 
denoted by inverted triangle). A leader sequence of 22 amino acids (underline) is predicted based upon comparison with other members of the β-defensin 
family. Cysteine residues conserved with other β-defensin genes are boxed. (b) Alignment of Defβ37/Pbd1 with the draft mouse genome sequence using 
BLAT. Defβ37/Pbd1 aligns with sequence on mouse chromosome 8 and is spliced into two exons separated by a 7.3 kb intron. Genscan and Fgenesh 
predict a gene corresponding to Pbd1. No public mouse mRNAs or ESTs align to the Defβ37/Pbd1 sequence. Defβ37/Pbd1 is flanked by β-defensins 1 and 
2. (c) Multiple protein sequence alignment with Defβ37/Pbd1 and β-defensin family members. Residues conserved in a majority of sequences are boxed in 
dark gray. Residues strongly similar to conserved sequences are boxed in light gray. Cysteine residues predicted to be involved in β-defensin activity are 
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system (Qiagen, Valencia, CA, USA). For libraries made from
whole prostate, equal amounts of RNA from each lobe were
pooled prior to cDNA synthesis. Approximately 1 µg of total
RNA from each tissue source was used in first strand cDNA
synthesis reactions using the SMART cDNA library construc-
tion kit in accordance with the manufacturer's protocol
(Clonetech, CA, USA). Second strand cDNA was synthesized
and amplified through 18-21 cycles of the PCR, digested with
SfiI and directionally ligated into the lambdaTriplEx2
phagemid. Phagemids were converted to pTriplEx2 plasmids
in the BM25.8 Escherichia coli strain. A total of 14 cDNA
libraries were constructed. From each library, between 3,000
and 15,000 bacterial clones were picked into 384-well plates
using a Q-pix robot (Genetix, OR, USA) and grown overnight
at 37°C in LB media supplemented with 8% glycerol. We used
384-pin-replicators (Genetix) to transfer directly to 10 µl
PCR reactions containing Triplex2 forward PCR primer (5'
CTCGGGAAGCGCGCCATTGTGTTGGT 3') and Triplex2
reverse PCR primer (5' ATACGACTCACTATAGGGCGAATT-
GGCC 3'). PCR reactions were incubated with 1.5 units of
exonuclease I (Epicentre) and 0.5 units of shrimp alkaline
phosphatase (USB) for 15 minutes at 37°C to remove primers
and nucleotide triphosphates. Pin-replicators were used to
transfer ~0.2 µl of purified PCR product to 5 µl
fluorescence-based sequencing reactions containing 0.6 µM
Triplex2 5'Seq primer (5' CTCGGGAAGCGCGCCATTGTGTT-
GGT 3'), 0.5 µL Big Dye Terminator (ABI), 4 mM Tris pH 9.0
and 1 mM EDTA. One urogenital sinus library (UGS02) was
derived from approximately 500 Balb/c strain fetal mice and
was synthesized using both oligo-dT and random hexamer
priming followed by size-selection for cDNAs greater than
500 basepairs. These cDNAs were ligated to BstXI and EcoRI
adaptors, cloned into pcDNAII plasmids (Invitrogen, CA,
USA) and sequenced as described above but with the follow-
ing primers: VN26 PCR (5' TTTCCCAGTCACGACGTTGTA
3'), VN27 PCR (5' GTGAGCGGATAACAATTTCAC 3'), M13R
5'Seq (5' GGAAACAGCTATGACCATG 3 ' ) .  D e t a i l e d  l i b r a r y
descriptions are available at the mouse prostate expression
database website [16,17].
Assembly and annotation of ESTs derived from the 
mouse prostate
Each cDNA was sequenced once to produce an EST averaging
500 bp in length. Each EST was screened for sequence com-
prising vectors, E. coli, repetitive elements and low complex-
ity regions using the RepeatMasker algorithm. Sequence
quality was determined using Phred basecalling software
[51]. Following quality assessment, ESTs comprised of >100
unmasked nucleotides with 80/100 bases demonstrating a
quality score exceeding 20 were included in the analysis. Each
EST was compared against the mouse reference sequence
database using the Basic Local Alignment Search Tool
(BLAST) [52] and assigned a corresponding gene annotation
if the BLAST score exceeded 1,100. A BLAST score of 1,100
represents a minimum match of 555 nucleotides with 100%
identity, or a longer sequence match with relatively few
mismatches or gaps in the alignment; a stringency suitable
for matching ESTs against curated gene sequences. The
remaining ESTs not matching a reference sequence with high
stringency were assembled into gene clusters using the Phrap
assembly software with minimum match length parameter
set to 60 and minimum score parameter set to 90 [53]. Con-
sensus sequences were determined and compared with
sequences in the UniGene, GenBank, and dbEST databases
[54] using BLAST. ESTs that received a BLAST score of 200
or better were assigned a database annotation. The remaining
ESTs were classified as unannotated. The number of ESTs
from each library corresponding to the same annotation were
enumerated and used for subsequent comparative determi-
nations of gene expression measurements.
ESTs and EST assemblies not receiving annotations in Uni-
Gene, GenBank or dbEST were further evaluated for
characteristics supporting their classification as genes as
opposed to artifacts such as genomic DNA. Sequences repre-
sented by only one EST were not further evaluated. ESTs rep-
resented in ≥ 2 different libraries were compared against the
mouse genome assembly (February 2003 freeze) using the
BLAT algorithm to assess for splicing and gene predictions
[55,56]. These sequences were further evaluated for protein
coding regions by conceptual translations of six possible
reading frames using a custom perl script. Sequences with
greater than 200 amino acids of translated sequence in any
reading frame were analyzed on the BLOCKS server [57], run
with default settings, to identify possible motifs. Conceptual
translations were also checked for protein similarity using the
PSI- and PHI-BLAST algorithms [58].
Virtual analysis of differential gene expression
To identify genes with restricted or enhanced expression in
the prostate relative to other mouse tissues, we searched the
UniGene database with each prostate TU and selected those
UniGene clusters containing sequences derived from two or
fewer non-prostate tissues. For the purposes of this screen the
terms 'urinary bladder', 'vesicular gland', 'Wolffian duct
includes surrounding region', 'testicles', 'Wolffian duct and
mullerian duct' were grouped into a 'genitourinary' category.
In addition, 'tumor biopsy sample', 'tumor gross tissue',
'pooled lung tumors', 'tumor metastatic to mammary', 'infil-
trating ductal carcinoma', 'spontaneous tumor metastatic to
mammary, and 'stem cell origin' were grouped under 'tumor'.
To identify genes differentially expressed in prostate develop-
ment or between mouse prostate lobes, we utilized the pro-
gram Identification of Differentially Expressed Genes 6 test
statistics (IDEG6) [59,60]. IDEG6 performs a normalization
calculation to adjust for libraries with different numbers of
ESTs. Six different algorithms are applied to the datasets to
determine those TUs with statistical differences in abundance
levels between two or more libraries. Romualdi et al.
identified the Audic-Claverie approach [18] as the best statis-
tical method for identifying differentially expressed genes inhttp://genomebiology.com/2003/4/12/R79 Genome Biology 2003,     Volume 4, Issue 12, Article R79       Abbott et al. R79.13
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pairwise comparisons [60], and we report the results of this
analysis using a significance level of p = 0.001 with the Bon-
ferroni correction to adjust for multiple comparisons. The
DLP01, CG02, VP01 and VP02 libraries were evaluated in a
pairwise fashion for the lobular comparison. Libraries
included in the developmental pairwise comparison were
UGS01, UGS02, NEONATAL, DAY10, DAY20, DAY35, a
pooled library for MONTH3 (represented by combined TUs
from the lobular comparison) and MONTH14. Genes and
ESTs exhibiting differential expression between distinct
developmental time points were grouped by hierarchical clus-
tering using the Cluster software [61]. Clusters were visual-
ized using Treeview [61].
Unannotated, putatively novel sequences determined to be
differentially expressed between prostate lobes were further
evaluated using PSI-BLAST (Position-Specific Iterated
BLAST) and PHI-BLAST (Pattern-Hit Initiated BLAST) [58].
Nucleotide sequences were translated using the ExPASy
Translate program [62] to identify open reading frames. ESTs
were also compared against the assembled mouse genome
(February 2003 freeze) through the University of Santa
Cruz's BLAST-Like Alignment Tool (BLAT) [56] to identify
spliced sequences and predicted genes.
Quantitative polymerase chain reaction
Quantitative PCR analysis of selected genes was performed to
confirm the virtual expression results. Approximately 2 ng of
cDNA from each prostate lobe was used as a template for PCR
reactions using buffers and instructions in accordance with
the manufacturer's protocol (Applied Biosystems Inc., CA,
USA). Reactions contained 1X SYBR Green master mix
(Applied Biosystems, Inc.), and 0.3 µM of oligonucleotide
primer pairs designed to amplify the following genes: proba-
sin (Pbsn): Forward- 5' GGTCATCATCCTCCTGCTCA 3',
Reverse- 5' AGGCCCGTCAATCTTCTTTTT 3' (79 bp ampli-
con); spermine binding protein (Sbp): Forward- 5' CCCA-
CATGCAGAGCCCAGAAA 3', Reverse- 5'
ATCCGCATGCCCTTGAGTTG 3' (95 bp amplicon); serine
protease inhibitor, Kazal type 3 (Spink3): Forward- 5' TAT-
AGTTCTTCTGGCTTTTGC 3', Reverse- 5' TCTATGCGTTTC-
CTGTTTTCA 3' (246 bp amplicon); onzin (alias placenta-
specific 8 (Plac8)): Forward- 5' TTCTGTCCTGTTTGCTCT-
GTG 3', Reverse- 5' TCATGGCTCTCCTCCTGTTA 3' (61 bp
amplicon); receptor (calcitonin) activity modifying protein 2
(Ramp2): Forward- 5' CTCATCCTTCCCACAGACCT 3',
Reverse- 5' TGTGTCGTGAGTCCCCTTTG 3' (61 bp ampli-
con); ventral prostate predominant 1 (Vpp1): Forward- 5'
TGCTGTCTGTCTGTCTTCTG 3', Reverse-5' CCATACTTATT-
GTTTCTCCTTTC 3' (126 bp amplicon); ribonuclease, RNAse
A Family, 1 (RNAse1): Forward- 5' AAGTCCCTCATTCTGTT-
TCCA 3', Reverse- 5' TATCCCGGCGTTTCATCATTT 3' (166
bp amplicon); EST similar to acrosomal vesicle protein 1: For-
ward- 5' TGTTCCTAGGCTCTCACTGC 3', Reverse- 5' CCAA-
GAGTAGCAACAAGAGG 3' (52 bp amplicon); prostate β-
defensin 1 (Pbd1): Forward- 5' GATCAAGTGTAT-
GCCAAAAATG 3', Reverse- 5' TTTATATGGCTTCAGT-
GCTCTA 3' (149 bp amplicon). Amplifications were
performed using a protocol of 95°C for 30 sec, 60°C for 30
sec, and 72°C for 30 sec for 40 cycles on the ABI 7700
sequence detector while recording fluorescence measure-
ments. Each reaction was performed in triplicate and cycle
numbers were normalized to a parallel ribosomal protein S16
control as previously described [63]. To determine the tissue
distribution of Pbd1, quantitative PCR was performed using
cDNAs derived from multiple mouse tissues according to the
supplier's protocol (Invitrogen).
Northern and dot blot analysis
Ten µg of total RNA from each prostate lobe and other mouse
tissues were fractionated on 1.2% agarose denaturing gels and
transferred to nylon membranes by a capillary method [64].
The mouse multiple tissue and master blots were obtained
from Clontech, CA, USA. Blots were hybridized with Defβ37/
Pdb1 cDNA probes labeled with [alpha-32P]dCTP by random
priming using the Rediprime II random primer labeling sys-
tem (Amersham, CA, USA) according to the manufacturer's
protocol. Blots were stripped and re-probed for β-actin as a
loading control. Filters were imaged and quantitated by using
a phosphor-capture screen and ImageQuant software (Amer-
sham, CA, USA).
Additional data files
The additional data files are available with this article and at
[17]: A table showing the genes that are differentially
expressed between developmental timepoints at a signifi-
cance level of p = 0.001, without the correction for multiple
comparisons (Additional data file 1), and a table of genes rep-
resented by more than two prostate ESTs and expressed in
fewer than two tissues in addition to the prostate (Additional
data file 2).
Additional data file 1 A table showing the genes that are differentially expressed between  developmental timepoints at a significance level of p = 0.001, with- out the correction for multiple comparisons A table showing the genes that are differentially expressed between  developmental timepoints at a significance level of p = 0.001, with- out the correction for multiple comparisons Click here for additional data file Additional data file 2 A table of genes represented by more than two prostate ESTs and  expressed in fewer than two tissues in addition to the prostate A table of genes represented by more than two prostate ESTs and  expressed in fewer than two tissues in addition to the prostate Click here for additional data file
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